PLAUR Antibody

中文名稱：

PLAUR兔多克隆抗體
貨號：

CSB-PA07505A0Rb
規格：

￥440
圖片：
IHC image of CSB-PA07505A0Rb diluted at 1:200 and staining in paraffin-embedded human brain tissue performed on a Leica BondTM system. After dewaxing and hydration, antigen retrieval was mediated by high pressure in a citrate buffer (pH 6.0). Section was blocked with 10% normal goat serum 30min at RT. Then primary antibody (1% BSA) was incubated at 4°C overnight. The primary is detected by a biotinylated secondary antibody and visualized using an HRP conjugated SP system.

Immunofluorescence staining of Hela cells with CSB-PA07505A0Rb at 1:133, counter-stained with DAPI. The cells were fixed in 4% formaldehyde, permeabilized using 0.2% Triton X-100 and blocked in 10% normal Goat Serum. The cells were then incubated with the antibody overnight at 4°C. The secondary antibody was Alexa Fluor 488-congugated AffiniPure Goat Anti-Rabbit IgG(H+L).

Western blot
All lanes: PLAUR antibody at 4µg/ml
Lane 1: Mouse brain tissue
Lane 2: A2780 whole cell lysate
Lane 3: MCF-7 whole cell lysate
Lane 4: Hela whole cell lysate
Lane 5: Colo320 whole cell lysate
Secondary
Goat polyclonal to rabbit IgG at 1/10000 dilution
Predicted band size: 37, 32, 33 kDa
Observed band size: 37 kDa
其他：

產品詳情
產品評價
相關產品
靶點詳情

產品詳情

產品名稱：

Rabbit anti-Homo sapiens (Human) PLAUR Polyclonal antibody
Uniprot No.：

Q03405
基因名：

PLAUR
別名：

CD 87 antibody; CD87 antibody; CD87 antigen antibody; MO 3 antibody; MO3 antibody; Monocyte activation antigen Mo3 antibody; Plasminogen activator receptor urokinase antibody; Plasminogen activator urokinase receptor antibody; PLAUR antibody; U PAR antibody; u plasminogen activator receptor antibody; U-PAR antibody; u-plasminogen activator receptor form 2 antibody; UPA receptor antibody; uPAR antibody; UPAR_HUMAN antibody; Urinary plasminogen activator receptor antibody; URKR antibody; Urokinase plasminogen activator receptor antibody; Urokinase plasminogen activator surface receptor antibody; urokinase-type plasminogen activator (uPA) receptor antibody
宿主：

Rabbit
反應種屬：

Human, Mouse
免疫原：

Recombinant Human Urokinase plasminogen activator surface receptor protein (23-305AA)
免疫原種屬：

Homo sapiens (Human)

標記方式：

Non-conjugated

本頁面中的產品，PLAUR Antibody (CSB-PA07505A0Rb)，的標記方式是Non-conjugated。對于PLAUR Antibody，我們還提供其他標記。見下表：

標記方式	貨號	產品名稱	應用
HRP	CSB-PA07505B0Rb	PLAUR Antibody, HRP conjugated	ELISA
FITC	CSB-PA07505C0Rb	PLAUR Antibody, FITC conjugated
Biotin	CSB-PA07505D0Rb	PLAUR Antibody, Biotin conjugated	ELISA

克隆類型：

Polyclonal
抗體亞型：

IgG
純化方式：

>95%, Protein G purified
濃度：

It differs from different batches. Please contact us to confirm it.
保存緩沖液：

Preservative: 0.03% Proclin 300
Constituents: 50% Glycerol, 0.01M PBS, PH 7.4
產品提供形式：

Liquid
應用范圍：

ELISA, WB, IHC, IF

推薦稀釋比：

Application	Recommended Dilution
WB	1:1000-1:5000
IHC	1:200-1:500
IF	1:50-1:200

Protocols：

ELISA Protocol
Western Blotting (WB) Protocol
Immunohistochemistry (IHC) Protocol
Immunofluorescence (IF) Protocol
儲存條件：

Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
貨期：

Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
用途：

For Research Use Only. Not for use in diagnostic or therapeutic procedures.

產品評價

靶點詳情

功能：

Acts as a receptor for urokinase plasminogen activator. Plays a role in localizing and promoting plasmin formation. Mediates the proteolysis-independent signal transduction activation effects of U-PA. It is subject to negative-feedback regulation by U-PA which cleaves it into an inactive form.
基因功能參考文獻：
1. In acutely admitted patients with COPD, elevated PLAUR levels were associated with increased risk of mortality. PMID: 29783959
2. This study shows that the D2A sequence of the UPAR induces cell growth through alphaVbeta3 integrin and EGFR. PMID: 29184982
3. High expression of U-PAR is associated with breast cancer. PMID: 29893327
4. suPAR is associated with the Coronary Artery Calcification score and is a risk factor for new-onset CVD in patients undergoing hemodialysis. PMID: 29734173
5. Elevated baseline soluble urokinase receptor concentrations independently associate with new-onset microalbuminuria in subjects at increased risk of developing type 2 diabetes. PMID: 28091558
6. suPAR levels were significantly higher Behcet's disease patients. PMID: 27171829
7. To develop enzyme-resistant analogues, we applied here the Retro-Inverso (RI) approach, whereby the topology of the side chains is maintained by inverting the sequence of the peptide and the chirality of all residues. Molecular dynamics suggests that peptide RI-3 adopts the turn structure typical of uPAR-FPR1 antagonists PMID: 28465589
8. results demonstrated that PLAUR induces geftinib-resistance through EGFR/p-AKT/survivin signaling pathway in gefitinib-resistant human lung adenocarcinoma cells. PLAUR could be a novel therapeutic target for gefitinib-resistant NSCLC patients. PMID: 29961070
9. High Upar expression is associated with breast cancer. PMID: 28498427
10. Circulating soluble uPAR levels are higher in patients with peripheral arterial disease, particularly in those with extensive atherosclerosis and are predictive of long term cardiovascular and PAD-related outcomes. PMID: 28728756
11. Data confirmed PLAUR and CDH11, both targets of miR-335, to be overexpressed in gastric cancer tissues. PMID: 29075357
12. Serum and urine concentration of suPAR did not different between different clinical patterns of nephrotic syndrome in children, regardless the immunosuppressive treatment used. PMID: 29775445
13. the present study demonstrated that EGF induced aggressiveness of gastric cancer cells by activating epithelial to mesenchymal transition, which involved the activation of the ERK1/2 pathway and, subsequently, uPAR expression PMID: 28849196
14. The results establish GDE3 as a negative regulator of the uPAR signaling network and, furthermore, highlight GPI-anchor hydrolysis as a cell-intrinsic mechanism to alter cell behavior. PMID: 28849762
15. uPAR and TF could potentially be attractive targets for molecular imaging and therapy in oral squamous cell carcinoma due to high positive expression rates and tumor-specific expression patterns. High uPAR expression was significantly associated with a reduced survival. PMID: 28841839
16. suPAR levels are significantly elevated in hemodialysis patients with ESRD and remain associated with adverse outcomes. PMID: 28495863
17. These findings may show that presenting a high level of suPAR in migraine patients with attack and aura results to predisposition to occurring on the symptoms and that high levels of suPAR, procalcitonin and fibrinogen in patients with migraine result in neurogenic inflammation during migraine headaches. PMID: 28553881
18. suPAR may be a good novel biomarker for systemic subclinical inflammation and immune activation linked to adolescent obesity. PMID: 28749394
19. IFN-gamma, CXCL16 and uPAR are promising as effective biomarkers of disease activity, renal damage, and the activity of pathological lesions in systemic lupus erythematosus. PMID: 28628472
20. Main associations between PLAUR (urokinase plasminogen activator receptor) single nucleotide polymorphisms (SNPs) and markers of airway remodelling, and immunohistochemical analyses PMID: 26869673
21. Increased uPAR expression was detected in the derma of psoriatic lesions and in the stroma surrounding tumor cells in basal cell carcinomas. PMID: 28429105
22. Plasma plasminogen activator urokinase receptor (P-suPAR) concentrations are elevated in acute alcohol pancreatitis (AAP) and correlate with the severity of the disease, suggesting P-suPAR may serve as a prognostic marker for AAP severity on admission. PMID: 27841794
23. We report on the impact of bispecific targeting on the toxicity risks associated with targeting of EGFR and uPAR . Our results show that eBAT is safe and potentially effective at biologically active doses despite EGFR targeting, supporting further translation for patients with sarcomas and other EGFR-expressing malignancies. PMID: 28193671
24. Improved positron emission tomography imaging of glioblastoma cancer using novel (68)Ga-labeled peptides targeting the urokinase-type plasminogen activator receptor (uPAR). PMID: 28316028
25. Sera and tissues from malignant mesothelioma (MM) patients showed significantly high plasminogen activator urokinase receptor (uPAR) levels, suggesting the pathogenic role of uPAR in the tumor biology of MM. PMID: 27602956
26. Levels of circulating cleaved soluble forms plasminogen activator urokinase receptor (DIIDIII-suPAR) in acute myeloid leukemia (AML) patients are higher as compared to controls and significantly decrease after the conditioning. PMID: 27517491
27. Serum soluble urokinase-type plasminogen activator receptor as a serum marker of inflammatory response that leads to tissue damage and surgical complication PMID: 27759946
28. Binding of uPAR to VN triggers integrin-mediated signals, which result in ERK1-2 and RAC activation, accumulation of ROS, and senescence. PMID: 28086938
29. Plasma levels of intact and cleaved urokinase plasminogen activator receptor do not hold important predictive or prognostic information in men with clinically localised prostate cancer. PMID: 28607123
30. This study provides novel data that elevated airway and blood uPAR is a feature of asthma and that blood uPAR is particularly related to severe, nonatopic asthma. PMID: 27624865
31. uPAR and mTORC2 are components of a single cell-signaling pathway. PMID: 27777073
32. Patients with high suPAR levels were more likely to have progression of their kidney disease. PMID: 28873129
33. Results provide evidence that uPAR enhances malignant potential of triple-negative breast cancer by directly interacting with uPA and IGF1R. PMID: 27502396
34. PLAUR to be essential for activation of Checkpoint kinase 1 (CHK1); maintenance of cell cycle arrest after DNA damage in a TP53-dependent manner; expression, nuclear import and recruitment to DNA-damage foci of RAD51 recombinase, the principal protein involved in the homologous recombination repair pathway. PMID: 27685627
35. The synergy of circulating factor suPAR and APOL1 G1 or G2 on alphavbeta3 integrin activation is a mechanism for CKD. PMID: 28650456
36. Patients with cancer were significantly older and had a higher burden of comorbidities and previous cancer diagnoses compared to patients who were not diagnosed with cancer. Previous cancer, C-reactive protein (CRP) and suPAR were significantly associated with newly diagnosed cancer during follow-up in multiple logistic regression analyses adjusted for age, sex and CRP PMID: 28393357
37. This is the first report that PGE2 -induced uPAR expression, which stimulates invasiveness of human gastric cancer AGS cells, is mediated by the EP2 receptor-dependent Src/EGFR/JNK1/2, Erk1/2/AP-1, and Src/EGFR/JNK1/2, Erk1/2/NF-kappaB cascades. PMID: 27377703
38. Studies indicate the feasibility of combining two U-PA receptor (uPAR)-targeted probes in a preclinical head and neck cancer model. PMID: 28039488
39. Results suggest that soluble urokinase-type plasminogen activator receptor levels are positively correlated with severity of acute pancreatitis. PMID: 27914940
40. our study indicates that suPAR increases in patients with AML and this situation is associated with poorer survival. suPAR can thus be used as a diagnostic and prognostic biomarker in AML and may help in the developing of specific therapeutic targets. PMID: 26376588
41. urokinase plasminogen activator receptor has a role in incidence of venous thromboembolism PMID: 26466866
42. Our study implies that both soluble UPAR and advanced echocardiography are useful diagnostic tools for identifying patients with diabetes at risk of future clinical heart disease PMID: 26951602
43. The effect of LIF and uPAR on trophoblast migration and invasion was mediated by PI3K/AKT signaling pathway. PMID: 27133045
44. findings showed that elevated plasma suPAR levels were independently associated with an increased risk of developing first-time myocardial infarction in an HIV-1-infected population PMID: 26365671
45. Soluble urokinase plasminogen activation receptor (suPAR) is an emerging new biomarker for prognosticating cardiovascular disease PMID: 27052059
46. we review the human and mouse Ly6/uPAR family gene and protein structure and genomic organization, expression, functions, and evolution, and introduce new names for novel family members PMID: 27098205
47. Report presence of urokinase-type plasminogen activator receptor in seminal plasma, focusing on its interesting role as reliable and sensitive marker of inflammation for the differential diagnosis of male accessory gland inflammation. PMID: 26384478
48. uPAR expression is higher in normal pregnant women than that in patients with threatened abortion. uPAR promotes trophoblast migration and invasion during embryo implantation as well as plays a role in trophoblast differentiation into syntrophoblasts. PMID: 26823748
49. results show that cleaved uPAR forms are significantly increased in patients with advanced prostate cancer. PMID: 26764285
50. Hypoxia enhanced the endogenous uPAR mRNA and protein expression.HIF-1 protein bound the putative HIF-1 response element on the uPAR promoter.uPAR protein expression was detected in cervical cancer but not in normal cervix or CIN. PMID: 26718775
顯示更多

收起更多
亞細胞定位：

Cell membrane. Cell projection, invadopodium membrane.; [Isoform 1]: Cell membrane; Lipid-anchor, GPI-anchor.; [Isoform 2]: Secreted.
組織特異性：

Expressed in neurons of the rolandic area of the brain (at protein level). Expressed in the brain.
數據庫鏈接：

HGNC: 9053

OMIM: 173391

KEGG: hsa:5329

STRING: 9606.ENSP00000339328

UniGene: Hs.466871

Most popular with customers

YWHAG Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
YWHAB Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF, FC

Species Reactivity: Human, Mouse, Rat
Phospho-YAP1 (S127) Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
XRCC5 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF

Species Reactivity: Human
XPNPEP1 Recombinant Monoclonal Antibody

Applications: ELISA, IHC, FC

Species Reactivity: Human
XDH Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
WT1 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
WFDC2 Recombinant Monoclonal Antibody

Applications: ELISA, WB, FC

Species Reactivity: Human